EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023

Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio

Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products

Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions

Stelis Biopharma updates on receipt of consideration from Syngene

Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025

Syngene concludes acquisition of biologics manufacturing facility from Stelis Biopharma

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases

Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates

The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation